146 related articles for article (PubMed ID: 20099118)
1. Preclinical development of AS04.
Garçon N
Methods Mol Biol; 2010; 626():15-27. PubMed ID: 20099118
[TBL] [Abstract][Full Text] [Related]
2. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity.
Didierlaurent AM; Morel S; Lockman L; Giannini SL; Bisteau M; Carlsen H; Kielland A; Vosters O; Vanderheyde N; Schiavetti F; Larocque D; Van Mechelen M; Garçon N
J Immunol; 2009 Nov; 183(10):6186-97. PubMed ID: 19864596
[TBL] [Abstract][Full Text] [Related]
3. Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach.
Garçon N; Morel S; Didierlaurent A; Descamps D; Wettendorff M; Van Mechelen M
BioDrugs; 2011 Aug; 25(4):217-26. PubMed ID: 21815697
[TBL] [Abstract][Full Text] [Related]
4. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
[TBL] [Abstract][Full Text] [Related]
5. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems.
Garçon N; Van Mechelen M
Expert Rev Vaccines; 2011 Apr; 10(4):471-86. PubMed ID: 21506645
[TBL] [Abstract][Full Text] [Related]
6. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
Schwarz TF
Adv Ther; 2009 Nov; 26(11):983-98. PubMed ID: 20024678
[TBL] [Abstract][Full Text] [Related]
7. New adjuvants in evolving vaccine strategies.
Buonaguro FM; Tornesello ML; Buonaguro L
Expert Opin Biol Ther; 2011 Jul; 11(7):827-32. PubMed ID: 21609186
[TBL] [Abstract][Full Text] [Related]
8. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines.
Verstraeten T; Descamps D; David MP; Zahaf T; Hardt K; Izurieta P; Dubin G; Breuer T
Vaccine; 2008 Dec; 26(51):6630-8. PubMed ID: 18845199
[TBL] [Abstract][Full Text] [Related]
9. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.
Giannini SL; Hanon E; Moris P; Van Mechelen M; Morel S; Dessy F; Fourneau MA; Colau B; Suzich J; Losonksy G; Martin MT; Dubin G; Wettendorff MA
Vaccine; 2006 Aug; 24(33-34):5937-49. PubMed ID: 16828940
[TBL] [Abstract][Full Text] [Related]
10. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention.
Schwarz TF
Expert Rev Vaccines; 2008 Dec; 7(10):1465-73. PubMed ID: 19053203
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of Antigen Adjuvanted with AS04 and Its Deposition in the Upper Respiratory Tract after Intranasal Administration.
Xu H; Alzhrani RF; Warnken ZN; Thakkar SG; Zeng M; Smyth HDC; Williams RO; Cui Z
Mol Pharm; 2020 Sep; 17(9):3259-3269. PubMed ID: 32787271
[TBL] [Abstract][Full Text] [Related]
12. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions.
Ulrich JT; Myers KR
Pharm Biotechnol; 1995; 6():495-524. PubMed ID: 7551233
[TBL] [Abstract][Full Text] [Related]
13. Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile.
Garçon N; Wettendorff M; Van Mechelen M
Expert Opin Biol Ther; 2011 May; 11(5):667-77. PubMed ID: 21457083
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of HPV and HBV vaccines: adjuvanticity of synthetic analogs of monophosphoryl lipid A combined with aluminum hydroxide.
Taleghani N; Bozorg A; Azimi A; Zamani H
APMIS; 2019 Mar; 127(3):150-157. PubMed ID: 30746792
[TBL] [Abstract][Full Text] [Related]
15. Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines.
Baldridge JR; Crane RT
Methods; 1999 Sep; 19(1):103-7. PubMed ID: 10525445
[TBL] [Abstract][Full Text] [Related]
16. Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults.
Vandepapelière P; Rehermann B; Koutsoukos M; Moris P; Garçon N; Wettendorff M; Leroux-Roels G
Vaccine; 2005 Apr; 23(20):2591-601. PubMed ID: 15780441
[TBL] [Abstract][Full Text] [Related]
17. Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favour of Th1 responses.
Puggioni F; Durham SR; Francis JN
Allergy; 2005 May; 60(5):678-84. PubMed ID: 15813815
[TBL] [Abstract][Full Text] [Related]
18. Safety evaluation of a new allergy vaccine containing the adjuvant monophosphoryl lipid A (MPL) for the treatment of grass pollen allergy.
Baldrick P; Richardson D; Wheeler AW; Woroniecki SR
J Appl Toxicol; 2004; 24(4):261-8. PubMed ID: 15300713
[TBL] [Abstract][Full Text] [Related]
19. New hepatitis B vaccine formulated with an improved adjuvant system.
Kundi M
Expert Rev Vaccines; 2007 Apr; 6(2):133-40. PubMed ID: 17408363
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patients.
Nevens F; Zuckerman JN; Burroughs AK; Jung MC; Bayas JM; Kallinowski B; Rivas EF; Duvoux C; Neuhaus P; Saliba F; Buti M; Zarski JP; Pons F; Vanlemmens C; Hamtiaux V; Stoffel M
Liver Transpl; 2006 Oct; 12(10):1489-95. PubMed ID: 16964595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
